CN101229291B - Chinese traditional medicine composition for treating virus hepatitis by immunoregulation - Google Patents

Chinese traditional medicine composition for treating virus hepatitis by immunoregulation Download PDF

Info

Publication number
CN101229291B
CN101229291B CN2007100780997A CN200710078099A CN101229291B CN 101229291 B CN101229291 B CN 101229291B CN 2007100780997 A CN2007100780997 A CN 2007100780997A CN 200710078099 A CN200710078099 A CN 200710078099A CN 101229291 B CN101229291 B CN 101229291B
Authority
CN
China
Prior art keywords
radix
hepatitis
prescription
chinese medicine
rhizoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007100780997A
Other languages
Chinese (zh)
Other versions
CN101229291A (en
Inventor
陈志强
陈峥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2007100780997A priority Critical patent/CN101229291B/en
Publication of CN101229291A publication Critical patent/CN101229291A/en
Application granted granted Critical
Publication of CN101229291B publication Critical patent/CN101229291B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a traditional Chinese medical composite prescription for treating viral hepatitis through immunomodulation. According to basic theory of dialectical treatment of hepatitis B of traditional Chinese medical science and the study basis to the traditional Chinese medicine of western medicine science, the invention adopts a medical sequential testing method to screen and study traditional Chinese medicine and divides the Chinese medicine compound into the following parts according to different stages of disease course: immunopotentiator composite prescription, immunosuppressant composite prescription, immune bidirectional regulator composite prescription and optimal immune modulator composite prescription; the invention can reasonably regulate the human body immune function by drug combination, improve immunity of the organism, generate antivirus substance and clear the hepatitis B virus gradually, thereby reaching the purpose of treating virus B hepatitis. The traditional Chinese medical composite prescription is suitable for treating various viral hepatitis and human body immune dysfunction diseases.

Description

Chinese medicine composition by the immune modulating treatment viral hepatitis
Technical field
The present invention relates to a kind of Chinese medicine composition by the immune modulating treatment viral hepatitis, is carrier with traditional Chinese herbal medicine specifically, adopts the important composition of modern medical service technology treatment viral hepatitis.
Background technology
China is hepatitis big country, and hepatitis b virus carrier accounts for the 10-20% of total population, and wherein 25% is chronic hepatitis B patient, sends out the patient based on person between twenty and fifty.Along with the unban population increase in density, the degree of crowding day by day increases, and the chance that hepatitis is propagated is more, and the sickness rate of hepatitis is higher.Chronic hepatitis B is a kind of chronic, infectious disease that is caused by hepatitis B virus (HBV), and serious harm health influences quality of life.Chronic hepatitis B is a kind of commonly encountered diseases, frequently-occurring disease.Can be divided into according to B-mode surface antigen (HBsAg) carrying rate: high popular district (>8%), in popular district (2%-7%), low popular district (<2%).China is one of high popular district.According to statistics, the present hepatitis B virus infection rate of China overview is: anti-HBc and/or anti-HBs positive person are about 60.7%; Non-infection population accounts for 26%; The male chronic asymptomatic HBsAg carrier of HBsAg is 10%; The chronic asymptomatic HBV carrier of HBsAg feminine gender is 2%.Type B viral hepatitis is a kind of infectious disease of serious harm human health.The easy chronicity of hepatitis B, easily develop into liver cirrhosis, and confidential relation is arranged with the morbidity of primary hepatocarcinoma.
The intravital virus of acute hepatitis b patient fails to be eliminated and body autoimmune function obstacle and irrational treatment for a long time, also can develop into the hepatitis B of going slowly.Conventional western medical treatment viral hepatitis B mainly is the plain and ucleosides antiviral drugs of application of interference, but this method can only suppress virus replication, and the course of treatment is long, economic cost is high, can not effectively remove hepatitis B virus, and hepatitis B surface antibody is not prone to.Because the treatment of the traditional Chinese medical science, Chinese medicine can only be a Yin Yang balancing, whole conditioning, do not talk clearly Chu and be immunostimulant, or immunosuppressant, immune dual opsonic action has just appearred in the integral body conditioning of the traditional Chinese medical science, show as antigen of hepatitis B virus, the high and low alternately appearance of antibody concentration index clinically, the serum biochemistry index is bad when showing the liver function fashion, is difficult to remove hepatitis B virus, so the hepatitis B refractory more.
Summary of the invention
The traditional Chinese medical science is paid attention to integrally-regulated to treatment of diseases, regulating YIN and YANG (interior environment) has specific characteristics, we are according to the rationale of tcm syndrome differentiation and treatment hepatitis B and the doctor trained in Western medicine research foundation to Chinese medicine, adopt medical science sequential trial method that Chinese medicine is carried out screening study, and at the different phase of disease course, Chinese prescription (with the doctor trained in Western medicine name) is divided into: immunostimulant prescription immunosuppressant prescription immunity two-ways regulation agent prescription is optimized immunomodulator (nerve-endocrine-immunological network regulator) prescription human body immune function is rationally adjusted, human body immune function is carried out the reasonable regulating action of use in conjunction/induce body produce the antiviral substance effect, effectively improve the immunity of organism situation, remove hepatitis B virus gradually.Anti--HBs occurs, recover liver function, reach the purpose of curing hepatitis B.The clinical treatment that is applicable to various viral hepatitis and human body immune function disorders of this Chinese medicine composition.
Concrete scheme is: following prescription by weight
1, immunostimulant prescription: Radix Ginseng 15-45 Radix Astragali 45-150 Radix Bupleuri 15-45 Rhizoma Curculiginis 15-45 Radix Polygoni Multiflori 30-60 Herba Epimedii 15-45 Radix Isatidis 45-75 Pericarpium Citri Reticulatae 15-45 Poria 45-75 Rhizoma Alismatis 30-45 Rhizoma Atractylodis Macrocephalae 45-75 Herba Menthae 15-30,
We are applicable to the patient of no jaundice hepatitis B and chronic viral hepatitis B (slightly).Occur in the application process glutamate pyruvate transaminase (GPT) millet straw change enzyme (GOT) raise two times/or occur jaundice clinically and can stop using.
2, immunosuppressant prescription: Herba Artemisiae Scopariae 30-75 Radix Et Rhizoma Rhei 15-150 Radix Bupleuri 15-45 Lignum Sappan 15-45 Flos Carthami 15-45 Radix Gentianae Macrophyllae 15-45 Herba Menthae 15-30 Radix Paeoniae Alba 30-45 Radix Glycyrrhizae 6-45,
We are applicable to that the Patients with Viral Hepatitis human body immune function crosses when strong, and clinical manifestation has jaundice person, can alleviate the super quick state of body, is not suitable for the removing virus of hepatitis B.
3, immune two-ways regulation agent prescription: Radix Bupleuri 15-45 Radix Paeoniae Alba 30-75 Radix Sophorae Flavescentis 20-45 Radix Isatidis 45-75 Pericarpium Citri Reticulatae 15-45 Rhizoma Zingiberis 15-45 Poria 45-75 Radix Glycyrrhizae 6-45 Radix Angelicae Sinensis 30-60 Fructus Amomi Rotundus 15-30 Rhizoma Atractylodis Macrocephalae 45-75 Herba Menthae 15-30 Polyporus 30-60 Cortex Magnoliae Officinalis 15-45
We are applicable to various, each phase viral hepatitis that cause of disease is not bright, to the animal economy adjustment, mainly are the clinical symptoms of improving the patient.
4, optimize immunomodulator (nerve-endocrine-immunological network regulator) prescription: Radix Ginseng 15-45 Radix Astragali 45-150 Radix Angelicae Sinensis 30-60 Poria 45-75 Radix Salviae Miltiorrhizae 45-75 Rhizoma Chuanxiong 15-45 Radix Bupleuri 15-45 Radix Paeoniae Rubra 30-60 Pericarpium Citri Reticulatae 15-45 Herba Menthae 15-30 Fructus Amomi Rotundus 15-30 Radix Isatidis 45-75 Radix Sophorae Flavescentis 20-45 Fructus Crataegi 45-60 processs Squama Manis 25-45 Herba Verbenae 20-45 red ganoderma 30-60
We are applicable to anicteric various viral hepatitis, can recover human body immune function, induce function to produce antiviral substance, remove hepatitis virus.
Good effect of the present invention is as follows:
The clinical treatment result
Respectively organize patient's hepatopathy blood serum designated object situation (routine number) before and after table 1 treatment
Figure GSB00000426302400041
1 group of selected 13 example, wherein male 8 examples, women 5 examples are used the immunostimulant treatment, and GPT, GOT occurring in thoughtful three weeks increases/jaundice and treat termination, use other scheme treatment instead.
Clinical practice draws as drawing a conclusion:
1, Chinese medicine individual event immune material reinforcing agent is used for acute hepatitis b, can make patient GPT, GOT rising and jaundice occur;
2, Chinese medicine individual event immune material inhibitor should be used for human body immune function and crosses when strong, jaundice person is arranged as the disease initial stage, can alleviate the super quick state of body, is not suitable for the removing virus of acute hepatitis b.
Bad when 3, the dual conditioner of Chinese medicine immunity can make acute viral hepatitis B patient's liver function fashion, HBV antigen, antibody concentration raise and reduce alternately and occur.
4, Chinese medicine immunosuppressant, immune dual conditioning all can not effectively be removed hepatitis B virus, and it is chronic to cause acute type B viral hepatitis to transfer to.
5, Chinese medicine is optimized immunomodulator (nerve-endocrine-immunological network is regulated), be to immune cell, the cellular neural factor and nerve-endocrine-immunological network play the promotion functional rehabilitation, in the generation of various immune materials such as interferon, play short effect or the synergism of inducing, promote the liver reticuloendothelial cell to bring back to life, quicken reparation and the regeneration of stem cell, recover liver function, transfer self motility of liver simultaneously, give full play to antiviral effect, alleviate the damage of paathogenic factor to body, thereby improve the resistance against diseases of body, reach and remove virus, cure the purpose of hepatitis.
The specific embodiment
The present invention is according to the rationale of differential diagnosis in tcm treatment hepatitis B and the doctor trained in Western medicine research foundation to Chinese medicine, adopt medical science sequential trial method that Chinese medicine is carried out screening study, and at the different phase of disease course, Chinese medicine composition (with the doctor trained in Western medicine name) is divided into: immunostimulant prescription immunosuppressant prescription immunity two-ways regulation agent prescription is optimized immunomodulator (nerve-endocrine-immunological network regulator) prescription
1 immunostimulant prescription: Radix Ginseng 30g Radix Astragali 90g Radix Bupleuri 30g Rhizoma Curculiginis 30g Radix Polygoni Multiflori 50g pubeseent epimedium herb 30g Radix Isatidis 60g Pericarpium Citri Reticulatae 30g Poria 60g Rhizoma Alismatis 40g Rhizoma Atractylodis Macrocephalae 60g Herba Menthae 20g,
We are applicable to the patient of acute no jaundice hepatitis B and chronic viral hepatitis B (slightly).Occur in the application process glutamate pyruvate transaminase (GPT) GUCAO change enzyme (GOT) raise two times/or occur jaundice clinically and can stop using.
2, immunosuppressant prescription: Herba Artemisiae Scopariae 60g Radix Et Rhizoma Rhei 90g Radix Bupleuri 30g Lignum Sappan 30g Flos Carthami 30g Radix Gentianae Macrophyllae 30g Herba Menthae 20g Radix Paeoniae Alba 40g Radix Glycyrrhizae 30g,
We are applicable to that viral hepatitis onlooker human body immune function crosses when strong, and clinical manifestation has jaundice person, can alleviate the super quick state of body, is not suitable for the removing virus of hepatitis B.
3, immune two-ways regulation prescription: Radix Bupleuri 30g Radix Paeoniae Alba 60g Radix Sophorae Flavescentis 30g Radix Isatidis 60g Pericarpium Citri Reticulatae 30g Rhizoma Zingiberis 30g Poria 60g Radix Glycyrrhizae 40g Radix Angelicae Sinensis 50g Semen Vignae Cylindricae bandit 20g Herba Menthae 25g Polyporus 50g Cortex Magnoliae Officinalis 30g,
We are applicable to various, each phase viral hepatitis that cause of disease is not bright, to the animal economy conditioning, mainly are the clinical symptoms of improving the patient.
4, optimize immunomodulator (nerve-endocrine-immunological network regulator) prescription: Radix Ginseng 30g Radix Astragali 90g Radix Angelicae Sinensis 50g Poria 60g Radix Salviae Miltiorrhizae 60g Rhizoma Chuanxiong 30g Radix Bupleuri 30g Radix Paeoniae Rubra 50g Pericarpium Citri Reticulatae 30g Herba Menthae 20g Semen Vignae Cylindricae bandit 20g Radix Isatidis 60g Radix Sophorae Flavescentis 30g Fructus Crataegi 50g processs Squama Manis 30g Herba Verbenae 30g red ganoderma 50g
We are applicable to anicteric various viral hepatitis, can recover human body immune function, induce body to produce antiviral substance, remove hepatitis virus.
Process
The Chinese medicine immunostimulant is regulated, the Chinese medicine immunosuppressant is regulated, Chinese medicine immunity two-ways regulation and Chinese medicine are optimized in the complete dosage form of immunomodulating (nerve-endocrine-immunological network is regulated) and are divided water solublity, fat-soluble and volatile medicine, with concentrate drying behind the water soluble drug mixing decocting, fat-soluble and volatile medicine, with concentrate drying behind the water soluble drug mixing decocting, volatile medicine adds the decocting evaporation, adopt closed recovery, fat-soluble medicine is pulverized, cross 120 mesh sieves, high temperature sterilize is then by various requirement mixed-forming (powder, capsule, tablet, electuary or water preparation).
Described immunostimulant prescription is applicable to anicteric various viral hepatitis, can recover human body immune function, induce body to produce antiviral substance, removes hepatitis virus,
Described immunosuppressant prescription is applicable to that the Patients with Viral Hepatitis human body immune function crosses when strong, and clinical manifestation has jaundice person, can alleviate the super quick state of body, is not suitable for the removing virus of hepatitis B,
Described immune two-ways regulation agent prescription is applicable to various, each phase viral hepatitis that cause of disease is not bright, to the animal economy conditioning, mainly is the clinical symptoms of improving the patient,
Described optimization immunomodulator prescription is applicable to the patient of acute no jaundice hepatitis B and chronic hepatitis (slightly).Occur in the application process in the paddy transaminase (GPT) millet straw change enzyme (GOT) raise two times/or occur jaundice clinically and can stop using.

Claims (1)

1. Chinese medicine composition by the immune modulating treatment viral hepatitis, it is characterized in that: it comprises four Chinese medicine composition prescriptions at the different phase drug combination of disease course: following prescription by weight,
The immunostimulant prescription:
Radix Ginseng 15-45 Radix Astragali 45-150 Radix Bupleuri 15-45 Rhizoma Curculiginis 15-45 Radix Polygoni Multiflori 30-60 Herba Epimedii 15-45,
Radix Isatidis 45-75 Pericarpium Citri Reticulatae 15-45 Poria 45-75 Rhizoma Alismatis 30-45 Rhizoma Atractylodis Macrocephalae 45-75 Herba Menthae 15-30,
The immunosuppressant prescription:
Herba Artemisiae Scopariae 30-75 Radix Et Rhizoma Rhei 15-150 Radix Bupleuri 15-45 Lignum Sappan 15-45 Flos Carthami 15-45 Radix Gentianae Macrophyllae 15-45 Herba Menthae 15-30 Radix Paeoniae Alba 30-45 Radix Glycyrrhizae 6-45,
Immunity two-ways regulation agent prescription:
Radix Bupleuri 15-45 Radix Paeoniae Alba 30-75 Radix Sophorae Flavescentis 20-45 Radix Isatidis 45-75 Pericarpium Citri Reticulatae 15-45 Rhizoma Zingiberis 15-45 Poria 45-75 Radix Glycyrrhizae 6-45 Radix Angelicae Sinensis 30-60 Fructus Amomi Rotundus 15-30 Rhizoma Atractylodis Macrocephalae 45-75 Herba Menthae 15-30 Polyporus 30-60 Cortex Magnoliae Officinalis 15-45,
Optimize the immunomodulator prescription:
Radix Ginseng 15-45 Radix Astragali 45-150 Radix Angelicae Sinensis 30-60 Poria 45-75 Radix Salviae Miltiorrhizae 45-75 Rhizoma Chuanxiong 15-45 Radix Bupleuri 15-45 Radix Paeoniae Rubra 30-60 Pericarpium Citri Reticulatae 15-45 Herba Menthae 15-30 Fructus Amomi Rotundus 15-30 Radix Isatidis 45-75.
CN2007100780997A 2007-12-26 2007-12-26 Chinese traditional medicine composition for treating virus hepatitis by immunoregulation Expired - Fee Related CN101229291B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2007100780997A CN101229291B (en) 2007-12-26 2007-12-26 Chinese traditional medicine composition for treating virus hepatitis by immunoregulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2007100780997A CN101229291B (en) 2007-12-26 2007-12-26 Chinese traditional medicine composition for treating virus hepatitis by immunoregulation

Publications (2)

Publication Number Publication Date
CN101229291A CN101229291A (en) 2008-07-30
CN101229291B true CN101229291B (en) 2011-05-25

Family

ID=39896304

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007100780997A Expired - Fee Related CN101229291B (en) 2007-12-26 2007-12-26 Chinese traditional medicine composition for treating virus hepatitis by immunoregulation

Country Status (1)

Country Link
CN (1) CN101229291B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101179171B1 (en) * 2008-08-14 2012-09-03 주식회사 운화 Composition for Preventing or Treating Hepatitic Disease Comprising Plant Stem Cell Line Derived from Cambium of Panax ginseng Including Wild Ginseng or Ginseng

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
周婉英.试论病毒性肝炎的中医治疗.哈尔滨医药第25卷 第4期.2005,第25卷(第4期),52-53.
周婉英.试论病毒性肝炎的中医治疗.哈尔滨医药第25卷 第4期.2005,第25卷(第4期),52-53. *
陈忻,张楠.中药治疗病毒性肝炎的药理学基础辨析.陕西中医第28卷 第1期.2007,第28卷(第1期),73-76.
陈忻,张楠.中药治疗病毒性肝炎的药理学基础辨析.陕西中医第28卷 第1期.2007,第28卷(第1期),73-76. *

Also Published As

Publication number Publication date
CN101229291A (en) 2008-07-30

Similar Documents

Publication Publication Date Title
CN102319407B (en) Traditional Chinese medicine for treating gastroptosis and extraction method thereof
CN1562160A (en) Composite medicine for treating hepatitis B complication
CN102319408B (en) Chinese medicine for strengthening spleen, eliminating dampness and treating gastroptosis and extraction method thereof
CN1692939A (en) Traditional Chinese medicine pill for treating hepatitis B, and its prepn. method
CN101647948A (en) Traditional Chinese medicine for treating viral hepatitis B and initial hepatocirrhosis and preparation method thereof
CN101361946B (en) Traditional Chinese medicine combination for treating hepatitis B
CN101152539A (en) Traditional Chinese medicine for treating acute icteric hepatitis
CN101129617A (en) Traditional Chinese medicine for treating liver cirrhosis
CN1539441A (en) Compounded medicine for anti pathogeny and immunoenhancement
CN1232288C (en) Chinese medicine aqueous pill preparation for treating hepatitis B and its preparation process
CN1186687A (en) Cancer preventing curing medicine series and its preparation
CN101167932A (en) Traditional Chinese medicine for treating chronic hepatitis B
CN1320914C (en) Menstruation regulating powder
CN101229291B (en) Chinese traditional medicine composition for treating virus hepatitis by immunoregulation
CN102327572A (en) Chinese medicament for invigorating primordial energy and treating gastroptosis and extraction method thereof
CN1066628C (en) Medicine for chronic hepatitis B and its preparation
CN104147526A (en) Traditional Chinese medicine particles for treating icteric hepatitis and preparation method thereof
CN101450203A (en) Oral liquid for treating hemiplegia
CN1090183A (en) Artemisia scoparia and ginseng pellet for mourishing liver and method for production thereof
CN1058911A (en) The compound method of capsule for curing tumour
CN101278982A (en) Chinese medicine compound preparation for curing acute or chronic hepatitis B and method of preparing the same
CN100518800C (en) Medicinal composition for treating hepatitis B
CN104127602A (en) Traditional Chinese medicine for treating fatty liver
CN102949658B (en) Drug formula for treating hepatitis
CN1371714A (en) Powder medicine for treating liver disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110525

Termination date: 20111226